|
Protein
|
MCI vs. ND
|
AD vs. ND
|
Amyloid-positive vs. amyloid-negative
|
Tau-positive vs. tau-negative
|
|---|
|
VEGF
|
n.s.
|
n.s.
|
0.9
|
0.9
|
|
sVEGFR-1
|
n.s.
|
n.s.
|
1.1
|
1.3
|
|
MCP-1
|
n.s.
|
n.s.
|
n.s.
|
1.1
|
|
IP-10
|
n.s.
|
n.s.
|
n.s.
|
1.2
|
|
IL-6
|
n.s.
|
n.s.
|
n.s.
|
n.s.
|
|
IL-8
|
n.s.
|
n.s.
|
n.s.
|
n.s.
|
|
SAA
|
n.s.
|
n.s.
|
n.s.
|
n.s.
|
|
CRP
|
0.6
|
0.5
|
0.5
|
0.7
|
|
sICAM-1
|
n.s.
|
n.s.
|
1.1
|
1.1
|
|
sVCAM-1
|
n.s.
|
n.s.
|
1.1
|
1.2
|
|
MIF
|
n.s.
|
n.s.
|
n.s.
|
1.3
|
|
C1q
|
n.s.
|
n.s.
|
n.s.
|
1.3
|
|
C3aDesArg
|
n.s.
|
n.s.
|
n.s.
|
n.s.
|
|
sIL-1RAcP
|
n.s.
|
n.s.
|
1.1
|
1.1
|
|
sTREM2
|
1.4
|
1.4
|
1.4
|
1.7
|
- Abbreviations: Aβ
40
β-Amyloid 1–40, Aβ
42
β-Amyloid 1–42, AD Patients with Alzheimer’s disease, CRP C-reactive protein, IL Interleukin, IP-10 Interferon-γ-induced protein 10, MCI Patients with mild cognitive impairment, MCP-1 Monocyte chemoattractant protein 1, MIF Macrophage migration inhibitory factor, ND Nondemented subjects, SAA Serum amyloid A protein, sICAM-1 Soluble intercellular adhesion molecule 1, sIL-1RAcP Soluble inhibition of soluble interleukin-1 receptor accessory protein, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, sVCAM-1 Soluble vascular cell adhesion molecule 1 factor, sVEGFR-1 Soluble vascular endothelial growth factor receptor 1, VEGF Vascular endothelial growth
- The table lists only significant comparisons and only fold changes of median values. Insignificant changes are marked as not significant (n.s.). Amyloid pathology was defined by Aβ42/Aβ40 ratio; tau pathology was defined by total-tau. For detailed descriptions of median values, SDs, and ranges, see Additional file 2, page 8 and following)
